12:00 AM
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Contrave: Phase III ongoing

Orexigen said it expects to complete enrollment in 4Q12 in the long-term, double-blind, placebo-controlled, U.S. Phase III (Light Study) trial of Contrave, a quarter earlier than previously expected. The study, which started in June with a goal to enroll up to 10,000 patients, has enrolled more than 4,500 patients as of Aug. 31. Orexigen expects to reach the number of MACE needed to conduct an interim analysis next year....

Read the full 321 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >